Introduction {#Sec1}
============

The incidence of prostate cancer is increasing among Japanese males, with an estimated 86,100 new cases diagnosed by the National Cancer Center Japan in 2017 \[[@CR1]\]. For patients with metastatic disease, recent advances in treatment strategies have improved their prognosis and disease management. As the most frequent metastatic site of prostate cancer is bone, it is important to treat bone metastases in order to reduce the incidence of skeletal complications and improve patients' quality of life.

In Japan, various therapeutic options are now available for the treatment of metastatic prostate cancer. As a result, clinicians are often faced with the daunting challenge of determining the optimal management strategy for an individual patient, including diagnosis and monitoring. To facilitate the decision-making process regarding the optimal treatment for a patient who has castration-resistant prostate cancer (CRPC) with bone metastases, a thorough review of the recent advances in basic and clinical research, which have resulted in the introduction of drugs with novel modalities, is required .

For decades, prostate cancer was treated primarily with androgen deprivation therapy (ADT). Docetaxel (DOC) was introduced at the beginning of the twenty-first century and has proven to be effective in the treatment of CRPC. In 2014, enzalutamide (ENZ) and abiraterone (ABI) were introduced in Japan as treatments for CRPC, as was cabazitaxel, after trials reported improvements in survival following treatment with DOC. Bone-targeted therapy with the alpha emitter radium-223 dichloride (Ra-223) was approved in Japan in June 2016. Ra-223 is the first agent found to improve both overall survival (OS) and time to symptomatic skeletal events, as shown in the ALSYMPCA trial \[[@CR2], [@CR3]\]; however, optimal patient selection and the optimal timing to initiate therapy have yet to be determined. Given the currently limited real-world experience with Ra-223, expert opinions, rather than clinical guidelines offering evidence-based recommendations, would be helpful for such decision-making in daily clinical practice.

We therefore organized a Japanese expert panel meeting for the management of prostate cancer with bone metastases, a forum at which experts could share their experiences and reach consensus on the key clinical questions related to the management of prostate cancer with bone metastases. The main focus of this meeting was to determine the optimal incorporation of Ra-223 into CRPC therapeutic regimens, but panelists also discussed other important and controversial topics in the areas of imaging and monitoring of prostate cancer.

Methods {#Sec2}
=======

Held on September 3, 2016, in Tokyo, Japan, the consensus panel included 27 experts from a variety of specialties involved in the management of prostate cancer (Table [1](#Tab1){ref-type="table"}). Of the panel participants, 96% were actively working at institutions that met facility requirements for the use of Ra-223, although 60% did not have any personal experience with Ra-223 treatment in clinical practice (except in clinical trials) at the time of meeting. Steering committee members were selected from the leadership of societies associated to the field and nominated by the participating panelists with no influence from the sponsor/funding agency.Table 1Panel membersRoleNameSpecialtyAffiliationsMeeting ChairSC MemberTakahashi, Shunji^a^Medical OncologyThe Cancer Institute Hospital of the Japanese Foundation for Cancer ResearchMeeting ChairSC MemberKinuya, SeigoNuclear MedicineKanazawa UniversityMeeting ChairSC MemberNonomura, NorioUrologyOsaka UniversityMeeting ChairSC MemberShinohara, NobuoUrologyHokkaido UniversityMeeting ChairSC MemberSuzuki, KazuhiroUrologyGunma UniversityMeeting ChairSC MemberSuzuki, HiroyoshiUrologyToho University Sakura Medical CenterMeeting ChairSC ChairKakehi, YoshiyukiUrologyKagawa UniversityPlenary SpeakerNakamura, KatsumasaRadiation OncologyHamamatsu University School of MedicinePlenary SpeakerSatoh, TakefumiUrologyKitasato University School of MedicinePlenary SpeakerTateishi, UkihideNuclear MedicineTokyo Medical and Dental UniversityPlenary SpeakerYoneda, ToshiyukiBasic Science ResearchIndiana University^b^PanelistHorikoshi, HiroyukiRadiation DiagnosticGunma Prefectural Cancer CenterPanelistIgawa, TsukasaUrologyKurume UniversityPanelistKamai, TakaoUrologyDokkyo Medical UniversityPanelistKoizumi, MitsuruNuclear MedicineThe Cancer Institute Hospital of the Japanese Foundation for Cancer ResearchPanelistKosaka, TakeoUrologyKeio UniversityPanelistMatsubara, NobuakiMedical OncologyNational Cancer Center Hospital EastPanelistMiyake, HideakiUrologyHamamatsu University School of MedicinePanelistMizokami, AtsushiUrologyKanazawa UniversityPanelistMizowaki, TakashiRadiation OncologyKyoto UniversityPanelistNakamura, NaokiRadiation OncologyNational Cancer Center Hospital EastPanelistNozawa, MasahiroUrologyKindai UniversityPanelistTakahashi, TakeoRadiation OncologySaitama Medical UniversityPanelistUemura, HirojiUrologyYokohama City University Medical CenterPanelistUemura, MotohideUrologyOsaka UniversityPanelistYokomizo, AkiraUrologyKyushu University^b^PanelistYoshimura, ManaNuclear MedicineTokyo Medical University*SC* Steering Committee^a^First/corresponding author^b^Affiliation at the time of meeting

Since the goal of the panel meeting was to address practical clinical needs, identifying real-world clinical questions was essential. The format of this meeting broadly followed that of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 \[[@CR4]\], and the simplified method of the Delphi process was used throughout \[[@CR5]\]. Before the meeting, members of the steering committee discussed and agreed upon the goal of the meeting. They identified clinical questions that would address issues pertinent to the management and monitoring of patients with CRPC with bone metastases. panelists were selected for their relevant expertise and were asked to submit examples of clinically relevant questions that are commonly raised during their daily practice. Starting with the list of clinical questions in the current Japanese Urological Association Guidelines, panelists deleted questions that were not clinically relevant to the topic on hand and added others they expected to be asked. The questions gathered using this process were categorized and prioritized by the steering committee, and the final version of the list was presented at the consensus panel meeting.

During the forum, all of the questions were presented to the panel in a multiple-choice format. panelists were polled anonymously using an electronic voting system. Those who were unable to vote for a best choice for any reason could choose 'abstain' as an option (see Electronic Supplementary Material \[ESM\] Table S1 for details). Each question was voted on only once, and there was no option to re-vote. After voting, the panel discussed the results and shared opinions.

The data presented in this consensus document are based on the voting results and related discussions and, therefore, do not report on research conducted on human subjects. This article does not contain any studies with human participants or animals performed by any of the authors. All panelists have reviewed and approved this manuscript.

Results {#Sec3}
=======

The voting results on the questions are discussed in detail in the following sub-sections, with the complete dataset shown in the ESM Table S1 and ESM Figs. S1--S30. The total number of voters for each question included those who chose to abstain; however, the numbers vary between questions because some panelists did not vote on all questions.

Management of Castration-Sensitive Prostate Cancer {#Sec4}
--------------------------------------------------

First we queried the panelists about their practices in the management of castration-sensitive prostate cancer (CSPC) and the assessment and treatment of bone disease in CSPC.

### Combined Androgen Blockade as Primary ADT {#Sec5}

At the time of this consensus meeting the Japanese Urological Association Guidelines recommended combined androgen blockade (CAB) as the primary ADT (PADT) in patients with M1 prostate cancer \[[@CR6]\], and 73% (19/26) of the panel members agreed with that recommendation. In contrast, half of the panel at the APCCC 2015 did not recommend CAB as treatment \[[@CR7]\].

### Treatment Strategy for Patients with Oligometastases {#Sec6}

According to a recent multi-institutional analysis, stereotactic body radiotherapy (SBRT) is associated with a prolonged progression-free survival (PFS) in patients with oligometastatic prostate cancer recurrence who are treatment-naive \[[@CR8]\]. Azzam et al. also reported that prognosis was better for men with recurrent prostate cancer treated with SBRT if they had ≤ 4 metastases  \[[@CR9]\]. Regarding the treatment strategy for patients with oligometastases (≤ 3 \[bone, lymph node\]) at initial diagnosis, 38% of the panelists recommended drug treatment alone, 15% recommended 'radical therapy' in addition to drug treatment, and 27% recommended radiation to metastases in addition to drug treatment. Radical therapy may be an option for oligometastases, but it should only be taken after careful evaluation to prevent overlooking micro-metastases.

### Osteoclast-Targeting Agents for CSPC {#Sec7}

The panel members felt that regular osteoporosis diagnosis is important; however, as to the timing of initiation of bone-targeted therapies, the opinions of the panel members were divided. For patients with CSPC with bone metastases, 27% prescribe osteoclast-targeting agents (zoledronic acid or denosumab) to the majority of patients, while 34% prescribe these agents to a minority of selected patients due to their concern for adverse events, especially osteonecrosis of the jaw (Fig. [1](#Fig1){ref-type="fig"}). It should be noted that steoclast-targeting agents were not shown to improve patient prognosis in several randomized trial results available in 2016, such as the STAMPEDE trial \[[@CR10]\] and a meta-analysis \[[@CR11]\].Fig. 1Do you prescribe osteoclast-targeting agents (zoledronic acid or denosumab) in patients with CSPC with bone metastases? \[CQ6\]

### Initial Diagnosis of Bone Metastases {#Sec8}

A meta-analysis of studies comparing fluoro-2-deoxy-[d]{.smallcaps}-glucose positron emission tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI), and bone scintigraphy for the diagnosis of bone metastases found that PET and MRI were comparable and that both were more accurate than CT and bone scintigraphy for the diagnosis of bone metastases \[[@CR12]\]. On these questions, there was consensus within our panel, with 73% agreeing that bone scintigraphy alone is not sufficient for the initial diagnosis of bone metastases. There was also clear consensus, with the panel unanimously (100%) agreeing that an MRI should be performed to confirm a diagnosis of metastases when there are discrepancies between the CT scan and bone scintigraphy.

Management of Patients with CRPC {#Sec9}
--------------------------------

The panel members were queried on their practices in treating patients with CRPC with different types of disease progression.

### The Reason for Stopping or Changing Treatment for CRPC {#Sec10}

There was strong consensus (91%) that at least two of three criteria (prostate-specific antigen \[PSA\] progression, radiographic progression, and symptomatic progression) should be met before treatment was changed.

### Osteoclast-Targeted Agent for CRPC {#Sec11}

The panel was almost equally divided on the question of whether a change of drug or administration schedule is necessary if CRPC is diagnosed in a patient currently being treated with an osteoclast-targeting agent for CSPC with bone metastases. In contrast, for a patient who has not received such an agent, 83% recommended that an osteoclast-targeting agent be prescribed after the diagnosis of CRPC. The panel felt that the combined therapy would be an appropriate option, as suggested by the post hoc analysis from the COU-AA-302 study \[[@CR13]\]. Further trials are necessary to confirm the effectiveness of this treatment strategy and optimal patient selection.

### Treatment Strategies on Each Progression Status {#Sec12}

The panel members discussed treatment strategies for CRPC patients with multiple bone metastases but no visceral metastases (with good performance status \[PS\]).

#### Treatment strategy at diagnosis of CRPC (i.e., during PADT with good PS) {#Sec13}

Regarding treatment strategy at the diagnosis of CRPC, more than half of the panel members (62 vs. 50%) recommended a new androgen receptor (AR)-targeted agent (ABI or ENZ) for those patients with rising PSA level and radiographic progression; for patients with symptomatic progression, however, the panel was more divided with regards to treatment, with 27% supporting treatment with ABI or ENZ (± external beam radiotherapy \[EBRT\]), 36% supporting treatment with DOC (± EBRT), and 36% supporting treatment with Ra-223 (± EBRT) (Fig. [2](#Fig2){ref-type="fig"}). There is as yet no clear evidence showing which CRPC patients, with bone metastases only, should be treated with the new AR-targeted agents DOC or Ra-223. Some panelists recommended that patients with aggressive bone disease should be treated with DOC, while other panelists commented that only a few patients will have aggressive disease. Some panelists suggested that Ra-223 is more likely to be used for symptomatic patients in the near future.Fig. 2Next preferred treatment in CRPC patients with multiple bone metastases (no visceral metastases) during PADT (with good PS).*PSA* Prostate-specific antigen

#### Treatment Strategy After Failure of ABI or ENZ, No Prior DOC, and with Good PS {#Sec14}

Regarding treatment strategy after the failure of treatment with ABI or ENZ or in case of primary resistance to ABI or ENZ, 60% of the panel members recommended DOC for patients with rising PSA. The opinions of the panel were more divided for cases of acquired resistance, with 38% supporting treatment with DOC, 29% supporting treatment with Ra-223, and 19% supporting treatment with another new AR-targeted agent. The panel was also split regarding the treatment of patients with radiographic progression, with 41% recommending DOC and 45% recommending Ra-223. For patients with symptomatic progression, 59% recommended Ra-223 (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Preferred next treatment in CRPC patients with multiple bone metastases (no visceral metastases) during treatment with new AR-targeted agent (ENZ/ABI), with no prior exposure to DOC and with good PS

The voting results suggest that a majority of the panel members believe that Ra-223 is an appropriate option for patients with symptomatic progression, although 60% of them at the time of the panel meeting did not have real-world experience with the agent. When the panel members were asked whether they would want to prescribe Ra-223, in addition to new AR-targeted agents, if it were reimbursable, 67% voted 'Yes, in the majority of patients' and 14% voted 'Yes, in a minority of selected patients.' Further studies are necessary to develop evidence for reimbursement decisions.

### Treatment Strategy After DOC {#Sec15}

Regarding the next treatment option for patients who have received DOC for 10 cycles and whose PSA is stable and bone metastases on imaging indicate stable disease, 33% of the panel recommended discontinuation of DOC, while 22% recommended continuation of DOC and 22% recommended switching to Ra-223 (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4What is the next treatment option for CRPC patients with multiple bone metastases (no visceral metastasis) who have received DOC for 10 cycles and whose PSA is stable and bone metastases on imaging indicate stable disease? \[CQ35\]

The panel members discussed whether the use of Ra-223 in this setting should be recommended or not. The voting results varied depending on the patient's status, with 50, 76, and 81% of the panel members recommending the use of Ra-223 in patients with a rising PSA only, with radiographic progression, and with symptomatic progression, respectively (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5The use of Ra-223 in CRPC patients with multiple bone metastases (no visceral metastases) during DOC (with good PS)

### Treatment Strategy with Ra-223 {#Sec16}

The panel members discussed the optimal timing of Ra-223 treatment. There was consensus that its use before chemotherapy was the more reasonable option rather than treatment after chemotherapy. The rationale for this recommendation is that a course of Ra-223 therapy requires a 6-month interval, and the time at which subsequent chemotherapy can be initiated requires careful evaluation.

Ra-223 is associated with hematological adverse events. As a result, the panel recommended performing regular blood tests at least every 2--4 weeks.

Managing Bone Metastases in Patients with CRPC {#Sec17}
----------------------------------------------

The panel members addressed many questions on their experiences and preferences for managing and treating bone metastases in patients with CRPC.

### Monitoring Bone Metastases {#Sec18}

Regarding treatment monitoring of patients with CRPC with bone metastases, 52% of the panel members recommended bone scintigraphy on a regular basis. The Prostate Cancer Working Group 3 (PCWG3) recommended a monitoring frequency of 8--9 weeks for the first 24 weeks, then every 12 weeks for bone scans as well as CT/MRI \[[@CR14]\].

As to monitoring during treatment with Ra-223, the panel strongly (91%) recommended monitoring with CT scans to detect lymph node and/or visceral metastases. Altogether, 83% of the panel members also recommended regular monitoring of alkaline phosphatase (ALP) during treatment of CRPC with bone metastases.

### Definition of Progression of Bone Metastases {#Sec19}

To evaluate metastatic bone progression, the PCWG2 outlined the 2 + 2 rule that recommends using two additional scans to confirm the appearance of at least two new lesions compared to an initial post-treatment scan. This method was maintained in PCWG3 and further extended to define the progression from non-metastatic to metastatic CRPC \[[@CR15]\]. The rule is intended to distinguish bone scan 'flare' from actual disease progression. However, implementation of this rule in real-world practice does appear to be haphazard, with fewer than half of panelists adopting this recommendation for assessing progression of bone metastases by imaging. Discussion showed that the PCWG3 recommendation was generally considered applicable for the clinical trial setting.

The panel reached a consensus (77%) that at least two of three criteria (PSA progression, radiographic progression, and symptomatic progression) should be used as the definition of progression.

### Quantification of Bone Metastases {#Sec20}

The bone scan index (BSI), which is obtained using a computer-aided bone scan evaluation system, is anticipated to become an objective and quantitative clinical tool for evaluating bone metastases in prostate cancer \[[@CR16]\]. Most panelists did not use BSI in clinical practice, and BSI was thought by some panelists to be premature for use in practice.

### Re-Biopsy/Biopsy in CRPC {#Sec21}

In 2014, a European Expert Consensus Panel emphasized the importance of biopsy to further understand the heterogeneity of prostate cancer and to move treatment planning toward a decision-making that was more individualized to the needs of the patient \[[@CR17]\].

Conversely, in this forum, when asked if a re-biopsy of the primary tumor for patients who are diagnosed as CRPC is necessary, 77% of the panel voted 'No.' As to biopsy of the metastatic site, 64% voted 'No.' Most panelists considered re-biopsy of CRPC to have little significance for therapeutic decision-making and more significance for research.

### Response to Bone Pain {#Sec22}

The panel discussed the best treatment option for bone pain and recommended EBRT for patients who develop isolated pelvic bone pain and Ra-223 for patients who develop multiple or diffused bone pain at the pelvis and spine. Ra-223 following EBRT would be an appropriate option as well.

Discussion {#Sec23}
==========

The main objective of this meeting was to share opinions among experts and to provide guidelines that would facilitate clinicians to successfully incorporate Ra-223 into CRPC treatment. At the time of the meeting, 60% of the panel members had no experience with Ra-223 treatment in actual practice and the optimal treatment strategy with Ra-223 had not yet been established. However, there was consensus for a number of key areas, including appropriate patient selection and optimal timing of treatment with Ra-233, for which the consensus was that patients with symptomatic metastatic CRPC and Ra-223 before chemotherapy, respectively, would benefit the most patients.

For patients with CSPC, CAB therapy was recommended by most panelists, although by contrast half of the panelists in the APCCC 2015 were opposed to CAB. CAB has more efficacy than luteinizing hormone-releasing hormone (LHRH) agonists alone and can prevent flare phenomenon, but following the introduction of LHRH antagonists and new AR-targeted drugs in clinical practice, the significance of CAB as a treatment option is being re-considered.

New findings have been reported since the meeting and these should be taken into account when a treatment for metastatic CSPC is being considered. According to a systematic review and meta-analysis, DOC at the beginning of ADT therapy for metastatic CSPC resulted in significantly longer OS and PFS than that seen with ADT therapy alone \[[@CR11]\]. At the time of the meeting in September 2016, this benefit had not been confirmed; 62% of the panel wanted to use DOC with ADT in patients with CSPC with bone metastases, and 23% used this regimen in their practice. The panel stressed that DOC with ADT should be used only in appropriate patients and that careful patient selection is crucial. According to the randomized CHAARTED trial \[[@CR18]\], the regimen was most effective in patients with higher volume disease; however, those patients with high-volume disease may have a higher risk of chemotherapy intolerance, and the definition of 'high tumor volume' has not been established. Therefore, it was also stressed by the panelists that other factors, including Gleason score, response to ADT, and patient characteristics, should be taken into consideration, and that new biomarkers must be explored.

The publication of the results of two important studies have resulted in changes in the treatment recommendations for metastatic CSPC since this consensus forum was held. The LATITUDE study showed that the addition of ABI and prednisone to ADT therapy to treat newly diagnosed, high-risk metastatic CSPC improved OS when compared to ADT therapy alone \[[@CR19]\]. The STAMPEDE trial showed similar results, with improved OS and higher rates of failure free survival seen with the addition of ABI and prednisone to ADT therapeutic regimen in a more heterogeneous patient population that included those with locally advanced or metastatic CSPC \[[@CR20]\]. As a result of these studies, the addition of ABI and prednisone to ADT either before or after chemotherapy has been approved in Japan, as well as the USA and other countries, for high-risk CSPC \[[@CR21]\].

Most panelists recommended that patients be monitored for osteoporosis and that treatment be provided if necessary during ADT. All panelists recommended using MRI when there are discrepancies between bone scintigram and CT findings. Almost all panelists recommended monitoring ALP during CRPC treatment.

Osteoclast-targeting agents were recommended for CRPC with bone metastases, and osteoclast-targeted agents can be used in combination with Ra-223. Most panelists recommended Ra-223 for patients with bone metastases only and with radiographic or symptomatic progression.

For other clinical questions, consensus between panelists was harder to determine and requires results from ongoing and future clinical studies and progress on regulatory issues. The panel was divided on the treatment strategy for patients with oligometastases, with half recommending drug treatment and others recommending additional therapies, including radical therapy and radiation. The diagnosis of oligometastases is important, and the significance of MRI or PET must be considered. There were different opinions on the definition of 'castration,' with regards to the threshold testosterone levels of \< 50 ng/dL (conventional) or \< 20 ng/dL. In the COU-AA-02 study of ABI acetate, prognosis was different between threshold testosterone levels of \> 20 and ≤ 20 ng/dL, but in practice almost all patients have \< 20 ng/dL testosterone with an LHRH agonist.

Regarding the evaluation of progression, fewer than half of the panelists recommended the use of PCWG3 or BSI criteria for monitoring. Many panelists thought that the PCWG3 criteria seem difficult and that the BSI criteria are too preliminary for use in clinical practice. The timing for changing treatment by scintigram extension of disease (EOD) grading was divided between EOD 1--2, 2--3, and 3--4 and is probably dependent on which treatment is considered: Ra-223, DOC, or a new AR-targeting treatment.

The treatment choice by panelists for patients with CRPC with bone metastases varied depending on whether the disease status was PSA-only, radiographic progression, or symptomatic progression. It was recommended that bone metastases with PSA-only progression be treated with a new AR-targeted agent and that symptomatic bone metastases be treated with Ra-223. The combination therapy of ABI and Ra-223 was studied in a phase 3 randomized double-blind setting (ERA 223; NCT02043678) for CRPC patients with bone metastases, but due to the observation of an increased risk of fractures and death in the combination arm, the trial was unblinded in December 2017 before the scheduled end of the study. Analysis of these study data is currently being performed \[[@CR22], [@CR23]\].

The discussions and opinions of 27 Japanese experts on the treatment of prostate cancer are reported here. However, there are limitations to these data. First, these data represent the voting results of the meeting, and the treatment selections were not determined from the actual prescribing records. Due the progress of this therapeutic area, the participants may currently have different opinions.

This report is based on a consensus meeting held in 2016, and subsequent trial results and evidence influencing current therapeutic standards are not reflected in all of the voting results. However, it is important for physicians to know how our understanding of the optimal use of therapy has evolved to what is seen today by knowing the consensus formed at each milestone of development. Being familiar with these developmental steps is useful to improving our understanding of the rationale behind standard therapies and reinforces the education needed by physicians who must provide optimal treatments in this therapeutic area that has an increasing complexity of choices.

Conclusions {#Sec24}
===========

The panel was in consensus that the optimal timing of Ra-223 treatment is before chemotherapy rather after chemotherapy because a course of Ra-223 therapy requires a 6-month interval, and the time to which subsequent chemotherapy administration can be initiated requires careful evaluation. Data from this meeting inform the development of future discussions or contributions to the development of new guidelines.
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